iShares US Pharmaceuticals

Most Recent

  • uploads///aerial view of various medical pills pharmaceutical
    Company & Industry Overviews

    An Easier Way to Understand the Pharma Industry

    In 2018, the global pharmaceutical industry stood at $1.2 trillion, and experts expect $1.5 trillion by 2023. Here’s everything investors need to know.

    By Sybil Prowse
  • uploads///Keytruda
    Company & Industry Overviews

    Merck’s Keytruda Had 80% Growth in the Third Quarter

    Merck & Co.’s (MRK) Keytruda generated revenues of $1.9 billion in the third quarter, reflecting an ~80% YoY growth.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Pfizer’s Dividends and Earnings Quality

    Pfizer’s dividend yield is 3.15%. The company’s historical dividend yield was 3.53% in 2017, while the five-year average yield is 3.44%.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Did Pfizer Stock Fare in Q3 2018?

    Nineteen analysts currently track Pfizer stock. The consensus rating for Pfizer stands at 2.63, which represents a “hold.”

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What’s Driving Pfizer’s Revenue?

    Pfizer has divided its product portfolio into two segments: Innovative Health and Essential Health. It reports revenue for both these segments.

    By Mike Benson
  • uploads///syringe _
    Company & Industry Overviews

    Allergan’s Stock Price Performance in September

    On September 21, 23 analysts tracked Allergan (AGN) stock. Four analysts recommended a “strong buy,” and 12 analysts recommended a “buy.”

    By Mike Benson
  • uploads///Chart  EPS Growth Rate
    Company & Industry Overviews

    A Review of Pharma Stocks’ EPS Growth Rates

    In this article, we’ll compare the EPS growth rates of Eli Lilly (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Eli Lilly’s Business Segments Performed in Q2 2018

    Eli Lilly and Company reports its business revenue under two segments: the Human Pharmaceutical segment and Elanco, the Animal Health segment.

    By Mike Benson
  • uploads///thermometer _
    Company & Industry Overviews

    A Look at Allergan’s Valuation on August 16

    In this series, we’ll discuss Allergan’s valuation, segment and product performances, recent developments, and analyst recommendations.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    LLY’s Cardiovascular Products: Cialis and Effient Q2 Sales Fall

    Cialis reported revenues of $538.7 million in Q2 2018, a YoY 14.0% decrease compared to revenues of $627.3 million in Q1 2017.

    By Mike Benson
  • uploads///syringe _
    Company & Industry Overviews

    Pfizer’s Trazimera Approved in Europe

    Pfizer (PFE) announced in a press release today that the European Commission has approved Trazimera for HER2 overexpressing breast cancer and HER2 overexpressing gastric or gastroesophageal junction adenocarcinoma.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Analysts’ Estimates and Recommendations for Allergan on July 19

    Analysts expect Allergan’s second-quarter revenue to fall ~2.5% to $3.9 million compared to its revenue of $4.0 million in the second quarter of 2017.

    By Mike Benson
  • uploads///dna _
    Earnings Report

    Pfizer Reports 1Q18 Earnings and Revenue Growth

    Pfizer (PFE) released its 1Q18 earnings today, reporting another strong quarter for the Innovative health business.

    By Mike Benson
  • uploads///pill _
    Healthcare

    These Pharma Stocks Offer the Most Upside Potential

    In 2018, stock markets, especially in the pharmaceutical sector, have seen heightened volatility.

    By Kenneth Smith
  • uploads///dna _
    Company & Industry Overviews

    Merck’s Relebactam Met Primary Endpoints in Phase 3 Study

    Merck’s Relebactam is an investigational drug for the treatment of certain forms of imipenem-non-susceptible bacterial infections.

    By Mike Benson
  • uploads///Chart  MRK
    Company & Industry Overviews

    How Merck & Co. Stock Performed in 1Q18

    Merck & Co. stock has fallen ~6.4% in 1Q18, while it’s fallen ~5.2% YTD (year-to-date) as of April 6, 2018.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What’s Merck’s Valuation in March 2018?

    Merck (MRK) reported 3% growth in revenues to $10.4 billion during 4Q17 as compared to revenues of $10.1 billion in 4Q16.

    By Mike Benson
  • uploads///medicine _
    Company & Industry Overviews

    Pfizer’s Valuation Post-4Q17 Earnings

    Pfizer (PFE) reported revenue of $13.7 billion in 4Q17, a 1% rise compared to $13.6 billion in 4Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Analysts’ Estimates for Johnson & Johnson after 4Q17

    Analysts are estimating EPS of $8.01 on revenues of ~$80.9 billion for Johnson & Johnson in 2018.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Analysts’ Ratings and Recommendations for Eli Lilly

    Analysts expect Eli Lilly to report EPS of $1.07 on revenues of ~$5.9 billion during 4Q17.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Johnson & Johnson’s Recent Developments

    On January 3, 2018, the FDA approved the inclusion of real-world data in Invega Sustenna’s product label, based on the PRIDE study.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Pfizer: Analysts’ Ratings and Recommendations for 4Q17

    Wall Street analysts expect Pfizer’s (PFE) top line to increase ~0.7% to ~$13.72 billion in 4Q17. The EPS is expected to increase to $0.56 for 4Q17.

    By Mike Benson
  • uploads///Chart  Val
    Company & Industry Overviews

    Merck’s & Co.’s Valuation in January 2018

    For 3Q17, Merck surpassed Wall Street analysts’ estimates for EPS but missed the revenue estimate. It reported EPS of $1.11 on revenues of $10.3 billion.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Mylan’s Rest of the World Segment Performed in 3Q17

    Mylan’s (MYL) Rest of the World segment includes revenues from third-party sales of generics products and specialty segment products reported from countries including New Zealand, India, Japan, and Australia as well as emerging markets including Asia, Brazil, Africa, and the Middle East.

    By Mike Benson
  • uploads///Xyrem
    Company & Industry Overviews

    How Is Jazz Pharmaceuticals’ Xyrem Positioned after 3Q17?

    In 3Q17, Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenue of $303.9 million, which reflected a rise of ~6% on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///Chart  RevEPS
    Company & Industry Overviews

    Eli Lilly’s Valuation in December 2017

    Eli Lilly (LLY) surpassed analysts’ estimates for EPS and revenues and reported EPS of $1.05 on revenues of $5.7 billion in 3Q17.

    By Mike Benson
  • uploads///Chart  Harvoni
    Company & Industry Overviews

    Harvoni Sales Fall in 3Q17

    Gilead’s Harvoni Harvoni is one of Gilead Sciences’ (GILD) largest-selling drugs. A combination of Ledipasvir and Sofosbuvir, it is approved for the treatment of hepatitis C infections. Harvoni’s importance The above chart shows Harvoni revenue over the last few quarters. During 3Q17, Harvoni contributed ~15% of Gilead’s revenue, and in 2Q17, it contributed ~21%. Harvoni […]

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Breaking down Allergan’s Business Segments in 3Q17

    This segment’s revenues rose 18.7% YoY (year-over-year) to $1.72 billion in 3Q17, compared with $1.45 billion in 3Q16.

    By Mike Benson
  • uploads///Key risks facing Synergy Pharmaceuticals
    Company & Industry Overviews

    Synergy Pharmaceuticals Is Facing These Risks This November

    Synergy only started earning revenues after the launch of Trulance in March 2017. Prior to that, Synergy hadn’t earned any revenues.

    By Kenneth Smith
  • uploads///Chart  Keytruda
    Company & Industry Overviews

    Behind the Latest Developments for Merck’s Keytruda

    Keytruda (pembrolizumab) is a prescription medicine from Merck’s (MRK) immuno-oncology franchise used for the treatment of various tumors.

    By Mike Benson
  • uploads///Xyrem
    Company & Industry Overviews

    This Could Drive Jazz Pharmaceuticals’ Revenue Growth

    In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenues of ~$298 million, which represents ~6% growth YoY and ~10% growth QoQ.

    By Daniel Collins
  • uploads///Chart  Rev EPS
    Company & Industry Overviews

    Eli Lilly’s Valuations after Its 2Q17 Earnings

    Eli Lilly (LLY) surpassed Wall Street estimates in 2Q17, reporting earnings per share of $1.11 on revenues of ~$5.8 billion. Analysts estimated that the company would report EPS of $1.05 on revenues of $5.6 billion.

    By Mike Benson
  • uploads///SIP
    Company & Industry Overviews

    Pfizer’s Sterile Injection Pharmaceuticals in 2Q17 and 1H17

    In 1H17, Sulperazon reported revenues of ~$232 million for 15% growth on a YoY basis.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Johnson & Johnson’s 2Q17 Performance, by Segment

    Segment-wise performance Johnson & Johnson (JNJ) reported 2.9% growth in operating revenue between 2Q16 and 2Q17. However, the company missed analysts’ 2Q17 estimate and reported revenue of $18.8 billion due to a 1% foreign exchange impact. Analysts had forecast revenue of $19 billion. Johnson & Johnson’s business is broken down into the pharmaceuticals segment, consumer […]

    By Mike Benson
  • uploads///Virology
    Company & Industry Overviews

    How Merck’s Zepatier and Isentress Are Positioned after 2Q17

    In 2Q17, Merck’s (MRK) Zepatier generated revenues of ~$517 million compared to $112 million in 2Q16.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    The Future of JAZZ’s Low-Sodium Investigational Drugs

    A 9-mg dose of JAZZ’s Xyrem, which contains 1,640 mg of sodium, has caused physicians to be reluctant to prescribe the drug to ~20% of their patients.

    By Margaret Patrick
  • uploads///Chart  EPS
    Company & Industry Overviews

    Pfizer’s 2Q17 Earnings: What You Need to Know

    Pfizer (PFE) reported a 2% decline in its top line for its 2Q17 earnings, which were released on August 1.

    By Mike Benson
  • uploads///Chart  EPS
    Earnings Report

    Inside Pfizer’s 2Q17 Earnings: Analyst Estimates

    Pfizer (PFE) is set to release its 2Q17 earnings on August 1, 2017. Analysts estimate earnings per share of $0.66 on revenues of ~$13.1 billion for 2Q17.

    By Mike Benson
  • uploads///Chart  Rev
    Earnings Report

    Bristol-Myers Squibb Reports Growth in 2Q17

    Bristol-Myers Squibb’s top line rose nearly 6% to ~$5.1 billion in 2Q17 due to operational growth of 7% in its revenue.

    By Mike Benson
  • uploads///Chart  Revenues
    Earnings Report

    Eli Lilly’s 2Q17 Earnings Rose 8% Year-over-Year

    Eli Lilly and Company (LLY) released its 2Q17 earnings on July 25, 2017, reporting an 8.0% rise in its top line to $5.8 billion for 2Q17 compared to 2Q16.

    By Mike Benson
  • uploads///Chart  EPS
    Earnings Report

    Bristol-Myers Squibb’s 2Q17 Earnings: Analysts’ Estimates

    Headquartered in New York City, Bristol-Myers Squibb (BMY) is a leading American pharmaceutical company.

    By Mike Benson
  • uploads///Internal Medicine
    Company & Industry Overviews

    How Pfizer’s Internal Medicines Is Positioned in 2017

    In 2016, Pfizer’s (PFE) Chantix reported revenues of ~$842 million, which represents a ~25% YoY (year-over-year) rise.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    What Analysts Predict for Eli Lilly’s 2Q17 Earnings

    For 2Q17, analysts estimate that Eli Lilly will post EPS of $1.05 and revenues of $5.6 billion.

    By Mike Benson
  • uploads///Chart  Pharmaceutical
    Earnings Report

    Johnson & Johnson: Pharmaceuticals in 2Q17

    Pharmaceutical segment Johnson & Johnson’s (JNJ) pharmaceutical segment comprises its immunology, infectious disease, neuroscience, oncology, cardiovascular and metabolic, and pulmonary hypertension franchises. Immunology franchise The major blockbuster drugs under the immunology franchise are Remicade, Stelara, and Simponi/Simponi Aria. The immunology franchise reported revenue of $3 billion in 2Q17, including an operational decrease of ~1.9% and a […]

    By Mike Benson
  • uploads///Animal Health Revenues
    Company & Industry Overviews

    How Merck’s Animal Health Business Is Expected to Perform in 2017

    In 2016, Merck’s (MRK) Animal Health segment reported revenues of ~$3.5 billion, which reflected ~4% growth year-over-year.

    By Daniel Collins
  • uploads///Chart  Cons
    Earnings Report

    Johnson & Johnson’s 2Q17 Estimates: Consumer Healthcare

    Johnson & Johnson’s (JNJ) Consumer Healthcare segment includes the baby care, oral care, skincare, over-the-counter products, women’s health, and wound care franchises.

    By Mike Benson
  • uploads///Chart  EPS
    Company & Industry Overviews

    What Allergan’s Valuation as of July 13 Tells Us

    For 2Q17, Wall Street analysts estimate AGN’s EPS (earnings per share) to come in at $3.93, which would be a 17.5% growth over 2Q16.

    By Mike Benson
  • uploads///Chart  ZTS
    Miscellaneous

    Performance of Zoetis Stock in 2Q17

    Zoetis (ZTS) stock has risen ~17.3% in 2Q17, while it has risen ~15.4% year-to-date as of July 7, 2017.

    By Mike Benson
  • uploads///Chart  REVEAL
    Company & Industry Overviews

    Merck’s Anacetrapib and REVEAL Study

    Merck & Co.’s (MRK) Anacetrapib is an investigational drug developed for the treatment of hypercholesterolemia. The drug also reduces the risk of cardiovascular disease.

    By Mike Benson
  • uploads///chart_ __ _gbs
    Company & Industry Overviews

    Pfizer’s Progress on Its Group B Streptococcus Vaccine

    Pfizer (PFE) has started a Phase 1 clinical trial to evaluate an investigational vaccine for protection against Group B streptococcus in infants younger than three months.

    By Mike Benson
  • uploads///Chart  Humalog
    Company & Industry Overviews

    FDA Approves Eli Lilly’s Humalog Junior KwikPen

    Eli Lilly (LLY) announced that the US Food and Drug Administration (or FDA) approved the Humalog Junior KwikPen for finer dose adjustments in the treatment of patients with diabetes on June 13, 2017.

    By Mike Benson
  • uploads///Chart  EPS
    Company & Industry Overviews

    What Happened to Pfizer’s Valuation after 1Q17?

    Pfizer (PFE), a pharmaceutical giant headquartered in New York City, reported EPS (earnings per share) of $0.69 on revenues of ~$12.8 billion for 1Q17.

    By Mike Benson
  • uploads///Chart  EPS
    Earnings Report

    Analyzing Pfizer’s 1Q17 Earnings

    Pfizer (PFE) reported a 2% fall in its top line for 1Q17 as part of its latest earnings announcement on May 2, 2017.

    By Mike Benson
  • uploads///Chart  Oncology
    Earnings Report

    How Will Eli Lilly’s Alimta and Other Oncology Products Perform?

    Oncology contributes around 18.0% to Eli Lilly’s (LLY) total revenues. Key drugs in this segment include Alimta, Erbitux, and Cyramza.

    By Mike Benson
  • uploads///Healthcare Sector Outperforming Overall Market Since
    Macroeconomic Analysis

    The Larger Aims of Obamacare: An Overview

    The idea behind Obamacare was that it would embody legislation not only providing but mandating healthcare coverage for nearly everyone in the US.

    By Mary Sadler
  • uploads///National Health Expenditure as of
    Macroeconomic Analysis

    The Hybrid US Healthcare System: An Overview

    The US healthcare system is unique in the developed world as it lacks a uniform system and, according to Emanuel, had been largely inefficient before Obamacare.

    By Mary Sadler
  • uploads///Chart
    Company & Industry Overviews

    Mergers and Acquisitions in US Pharmaceuticals in 1Q17

    The US pharmaceutical sector is made up of different areas geared toward the development, production, and marketing of drugs. Let’s take a look at some of the sector’s 1Q17 mergers and acquisitions.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Johnson & Johnson’s Business Segment Performance

    Johnson & Johnson’s Medical Devices segment contributed nearly 35% to the company’s total revenues.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Eliquis: Bristol-Myers Squibb’s Key Cardiovascular Drug

    Bristol-Myers Squibb’s (BMY) cardiovascular segment consists of its key drug, Eliquis. The segment contributed nearly 18.0% to the company’s total revenues in 4Q16.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    How Did JNJ’s Pharmaceuticals Segment Perform in 4Q16?

    Johnson & Johnson’s (JNJ) pharmaceuticals segment consists of its immunology, infectious disease, neuroscience, oncology, and cardiovascular and metabolics franchises.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Mylan’s Recent Commercial and Product Developments

    Mylan’s recent commercial developments include the acquisition of the Cold-EEZE brand from ProPhase Labs and the acquisition of Meda AB.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Mylan’s EpiPen Controversy: Is It a Brand or a Generic?

    Mylan has been embroiled in a controversy over whether its EpiPen is classified as a generic or a branded product and whether its 500.0% price hike is justified.

    By Mike Benson
  • uploads///PD L avelumab
    Company & Industry Overviews

    Exploring Avelumab’s Opportunities in the PD-1/PD-L1 Space

    Pfizer plans to use avelumab, a PD-L1 (programmed death-ligand 1) class immuno-oncology product, as a backbone therapy in its immuno-oncology programs.

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    Pfizer Divests Hospira’s Infusion System Business to ICU Medical

    On October 6, 2016, the California, US-based ICU Medical entered into a definitive agreement to acquire Hospira’s Global Infusion System business.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Bristol-Myers Squibb Saw Improved Eliquis Sales in 3Q16

    Bristol-Myers Squibb’s (BMY) cardiovascular segment consists of key drug Eliquis. This segment contributed nearly 18% of total revenues for 3Q16.

    By Mike Benson
  • uploads///Hospira infusion divestment
    Company & Industry Overviews

    Pfizer’s Divestment of Hospira Infusion Systems

    On October 6, 2016, Pfizer (PFE) announced one deal to “off-load” all of the global infusion therapy business known as “Hospira Infusion Systems.”

    By Jillian Dabney
  • uploads///ANR
    Company & Industry Overviews

    What Do Analysts Have to Say about Bristol-Myers Squibb?

    Analyst recommendations for BMY Bristol-Myers Squibb (BMY) is a leading immuno-oncology company. According to a Bloomberg consensus of 26 brokerage firms recorded on October 5, 2016, 42.3% of analysts recommended Bristol as a “buy” and 50% of analysts issued a “hold” rating for the company. Around 7.7% of analysts rated the stock as a “sell.” The […]

    By Jillian Dabney
  • uploads/// Trump
    Company & Industry Overviews

    Analyzing Donald Trump’s Free-Market Healthcare

    While Clinton aims to retain and bolster the Affordable Care Act, Trump wants to replace it with a new act that encourages free-market competition.

    By VanEck
  • uploads///Chart
    Company & Industry Overviews

    Which Pfizer Products Reported Declining Sales?

    Products with declining revenues So far, we’ve discussed growth trends and positive growth products for Pfizer (PFE). Let’s now discuss the products that hampered growth. The overall share of revenues for the Essential Health business increased to 46% of total revenues in 2Q16 from 44% of total revenues in 2Q15, driven by revenue growth from […]

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    The Pfizer-Anacor Deal: A Review

    Pfizer-Anacor deal On June 23, 2016, Pfizer (PFE) completed the acquisition of Anacor Pharmaceuticals (ANAC). The stock transaction is valued at $99.25 per Anacor share, resulting in a total enterprise value of ~$5.2 billion. What is Anacor? Anacor is a California-based biopharmaceutical company. It is focused on developing and commercializing boron-based drugs for the treatment […]

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    A Look at the Pfizer-Medivation Deal

    Pfizer-Medivation deal On September 27, 2016, Pfizer (PFE) completed the acquisition of Medivation (MDVN). The stock transaction is valued at $81.50 per Medivation share, resulting in a total enterprise value of ~$14 billion. What is Medivation? Medivation is a California-based biopharmaceutical company. It is focused on developing and commercializing innovative therapies for the treatment of […]

    By Mike Benson
  • uploads///PFE AZN deal
    Company & Industry Overviews

    How Can Pfizer Revive Its Essential Health Business?

    On August 24, Pfizer (PFE) announced its acquisition of AstraZeneca’s (AZN) small-molecule anti-infective portfolio, which is primarily outside the United States.

    By Jillian Dabney
  • uploads///danaher biologics opportunity
    Company & Industry Overviews

    Acquiring Pall Corp. Still Breathing Life into Danaher

    The acquisition of Pall has allowed Danaher to strengthen its presence in the life sciences market.

    By Shannon Black
  • uploads///Prevnar
    Company & Industry Overviews

    Why Pfizer’s Vaccines Business Is Declining

    With the acquisition of Baxter’s marketed vaccines, Pfizer (PFE) gained access to NeisVac-C and FSME-IMMUN/TicoVac.

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    Analyzing Johnson & Johnson’s Business Segments

    Johnson & Johnson is classified into three business segments—Pharmaceuticals segment, Consumer segment, and Medical Devices segment.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Did Bristol-Myers Squibb’s Eliquis Perform?

    Bristol-Myers Squibb’s (BMY) cardiovascular segment consists of its key drug Eliquis. This segment contributed nearly 78% of total revenues for 2Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Recent Corporate and Pipeline Developments for Pfizer

    Pfizer acquired Bamboo Therapeutics, a biotechnology company focused on developing gene therapy for treating rare diseases.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Pfizer-Anacor Deal Completed in June 2016

    On June 23, 2016, Pfizer (PFE) completed the acquisition of Anacor Pharmaceuticals (ANAC).

    By Mike Benson
  • uploads///Celator pipeline
    Company & Industry Overviews

    How Can Celator’s Portfolio Complement Jazz Pharmaceuticals?

    Vyxeos would offer commercial synergies to the Jazz Pharmaceuticals portfolio in the form of a complementary targeted prescriber base of AML patients who undergo HSCT.

    By Jillian Dabney
  • uploads///ev to ebitda
    Company & Industry Overviews

    The Truth behind Horizon’s EV-to-EBITDA Performance

    On June 29, 2016, Horizon Pharma was trading at a forward EV-to-EBITDA multiple of 4.67x, which is at a discount when compared with peers.

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    What Can We Expect from the Pfizer-Anacor Deal?

    Pfizer (PFE) announced the acquisition of Anacor Pharmaceuticals (ANAC) on May 16, 2016. The deal closed on June 23, 2016.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    The Pfizer-Anacor Deal Wrapped Up in June: Now What?

    In the Pfizer-Anacor merger, which was completed on June 23, 2016, the stock transaction is valued at $99.25 per Anacor share.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Pfizer Continues Its Organic and Inorganic Growth

    Pfizer (PFE) completed the acquisition of Anacor Pharmaceuticals (ANAC) on June 23, 2016. The acquisition will strengthen Pfizer’s portfolio of inflammatory disease products.

    By Mike Benson
  • uploads///Chart
    Miscellaneous

    What the CHMP Just Recommended for Alkem’s Riluzole Alkem

    The European Medicines Agency’s CHMP (Committee for Medicinal Products for Human Use) recommended the suspension of Alkem’s Riluzole Alkem on June 24, 2016.

    By Mike Benson
  • uploads///Chart
    Miscellaneous

    Inside the CHMP’s Refusal of Novartis’s Arzerra as a Maintenance Treatment

    The European Medicines Agency’s CHMP gave a negative recommendation to Novartis’s Arzerra for use as a maintenance treatment for CLL on June 23, 2016.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Why Eliquis Matters to Bristol-Myers Squibb’s Cardiovascular Business

    Bristol-Myers Squibb’s (BMY) Cardiovascular segment includes the key drug Eliquis. The segment contributed nearly 16.7% of total revenues for 1Q16.

    By Mike Benson
  • uploads///specialty generics
    Earnings Report

    What to Expect from Mallinckrodt’s Specialty Generics Business

    The total contribution from Mallinckrodt’s Specialty Generics segment in fiscal 2Q16 stood at $264.4 million, which represents a 27% YoY decline.

    By Jillian Dabney
  • uploads///Chart
    Earnings Report

    Pfizer’s 1Q16 Earnings: Profitability and Financial Guidance

    Pfizer (PFE) reported an increase of ~19.7% in revenue during 1Q16. Revenue came in at $13.0 billion for 1Q16 as compared to $10.9 billion for 1Q15.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Pfizer’s 1Q16 Earnings: Products That Saw Sales Drop

    The overall share of revenue for Pfizer’s Established Products segment decreased to 44.6% in 1Q16 from 48.8% for 1Q15.

    By Mike Benson
  • uploads/// App Economy
    Macroeconomic Analysis

    What’s behind the US Economy’s Remarkable Labor Market Strength?

    The US labor market has shown tremendous resilience amid concerns over various issues, like aging demographics.

    By Rick Rieder
  • uploads///Chart
    Earnings Report

    Novartis’s 1Q16 Earnings Got a Neutral Response from Investors

    Novartis (NVS) released its 1Q16 earnings on April 21, 2016. It reported top-line growth of 1% at constant exchange rates for 1Q16—compared to 1Q15.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    A Segment-by-Segment Breakdown of JNJ’s 1Q16 Earnings

    The overall business of Johnson & Johnson (JNJ) is classified into three business segments: pharmaceuticals, consumer, and medical devices.

    By Mike Benson
  • uploads///Erwinaze revenue
    Company & Industry Overviews

    Could Supply Limit Growth for Erwinaze?

    As Jazz Pharmaceuticals’ (JAZZ) second-largest drug, Erwinaze earned $203 million, or ~15% of total net sales, in fiscal 2015.

    By Jillian Dabney
  • uploads///global pharma market size
    Company & Industry Overviews

    How Is the Global Pharmaceutical Industry Doing?

    Some of the challenges the pharmaceutical industry faces include R&D failures, changes in regulatory procedures, litigation, patent expiries, and foreign currency movements.

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    Checkmate-205: Studies Supporting Opdivo’s Application

    The Checkmate-205 study is the phase II study that compares safety and efficacy of Opdivo in the treatment of patients with relapsed or refractory classical Hodgkin lymphoma

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Opdivo: Bristol-Myers Squibb’s Blockbuster Drug

    Opdivo is a part of Bristol-Myers Squibb’s (BMY) alliance with Ono Pharmaceutical, and it reported revenues of $942 million in 2015.

    By Mike Benson
  • uploads///Actimmune
    Company & Industry Overviews

    Why Actimmune, Horizon’s Lead Orphan Product, Has Such Huge Potential

    After the Vidara merger in September 2014, Horizon Pharma gained access to Actimmune, which has been approved by the FDA for CGD and SMO.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    How Is Meda AB a Strategic Fit for Mylan’s Business?

    On February 10, 2016, Mylan (MYL) announced its decision to acquire Meda AB for a consideration of $9.9 billion through a public offer.

    By Margaret Patrick
  • uploads///Chart
    Earnings Report

    Understanding Future Estimates for Johnson & Johnson

    JNJ has surpassed all estimates for EPS in the past, and analysts estimate that JNJ will generate an EPS of $1.65 on revenues of ~$17.5 billion in 1Q16.

    By Mike Benson
  • uploads///patent cliff
    Company & Industry Overviews

    Drug Patent Expirations: $190 Billion Is Up for Grabs

    According to estimates by Evaluate Pharma, a whopping $120 billion in sales was lost to patent expirations between 2009 and 2014.

    By VanEck
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.